PI Industries (PIIND) Q1 25/26 earnings summary

Executive summary

• Q1 FY26 performance aligned with annual plans despite global AgChem industry headwinds, with revenue at INR 19,005 million, EBITDA at INR 5,219 million, and PAT at INR 4,000 million, all showing double-digit 3-year CAGR growth.

• Domestic business grew 6% year-over-year, supported by favorable monsoon forecasts and strong product portfolio; commercialized 2 new export and 2 domestic agri products.

• Pharma platform rebounded with 186-187% revenue growth year-over-year, driven by deeper relationships with biotech and big pharma.

• Biologicals segment faced a decline due to regulatory changes, with normalization dependent on government and court actions.

• Continued investment in R&D, new product launches, and expansion into specialty chemicals and electronic chemicals.

Financial highlights

• Q1 FY26 consolidated revenue was INR 19,005 million, down 8% year-over-year but up 7% sequentially; 3-year Q1 CAGR stands at 7%.

• Gross margin expanded to 57.4%, up 5.7% year-over-year; EBITDA margin remained resilient at 27-27.5%.

• Net worth increased to INR 1,603 million; surplus cash net of debt at INR 41,554 million.

• Trade working capital days increased to 91 from 73 in March 2025, with inventory levels stable.

• Net profit declined 11% year-over-year; cash flow from operating activities was Rs. 2,168 million.

Outlook and guidance

• Expecting single-digit revenue growth for FY26, with sustained EBITDA margin and gross margin guidance at 50-52%.

• Pharma business on track for 75% revenue growth in FY26 with improved margins.

• Multiple growth levers: portfolio diversification, aggressive commercialization of 8-10 new products, and technology-driven expansion.

• Biologicals business expected to revive post regulatory clearance; cautious optimism amid inventory destocking and US tariff uncertainties.

• Planned capital expenditure of INR 700-800 crore for the year to support growth engines.